id: question_021
type: list
body: "For obesity treatment, which 10 protein targets have the most clinical-phase (phase 2+) compounds in ChEMBL?"

inspiration_keyword:
  keyword_id: KW-0550
  name: "Obesity"
  category: "Disease"

togomcp_databases_used:
  - mesh
  - chembl

verification_score:
  verifiability: 3
  rdf_necessity: 3
  scope: 3
  total: 9
  passed: true

pubmed_test:
  time_spent: "15 minutes"
  method: "Searched PubMed using multiple query strategies: (1) 'obesity drug targets clinical trials' returned 572 general articles but none providing systematic target ranking by compound count. (2) 'obesity protein targets phase 2 phase 3 compounds ranking' returned 0 results. Examined top 3 articles from first search - they discussed individual drugs (GLP-1RAs for Alzheimer's, psoriatic arthritis treatments) but did not provide comprehensive database-driven rankings of targets by clinical-phase compound counts."
  result: |
    PubMed searches returned either general review articles discussing individual obesity drugs and targets,
    or zero results for systematic ranking queries. The literature contains qualitative discussions of
    obesity drug targets but lacks quantitative systematic comparisons ranking targets by number of
    clinical-phase compounds. This ranking requires cross-database integration of MeSH disease
    classification with ChEMBL's curated drug development pipeline data, which cannot be replicated
    through literature searches alone.
  conclusion: "PASS (cannot answer from literature)"

sparql_queries:
  - query_number: 1
    database: "mesh"
    description: "Retrieve obesity MeSH descriptor with identifier and tree numbers for disease classification"
    query: |
      PREFIX mesh: <http://id.nlm.nih.gov/mesh/>
      PREFIX meshv: <http://id.nlm.nih.gov/mesh/vocab#>
      PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>
      
      SELECT ?label ?identifier ?annotation ?treeNumber
      FROM <http://id.nlm.nih.gov/mesh>
      WHERE {
        mesh:D009765 a meshv:TopicalDescriptor ;
                      rdfs:label ?label ;
                      meshv:identifier ?identifier .
        OPTIONAL { mesh:D009765 meshv:annotation ?annotation }
        OPTIONAL { 
          mesh:D009765 meshv:treeNumber ?tree .
          ?tree rdfs:label ?treeNumber
        }
      }
      LIMIT 5
    result_count: 2

  - query_number: 2
    database: "chembl"
    description: "Find all drug indications for obesity (checking MeSH term linking)"
    query: |
      PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>
      
      SELECT DISTINCT ?meshHeading ?molecule ?moleculeLabel ?phase
      FROM <http://rdf.ebi.ac.uk/dataset/chembl>
      WHERE {
        ?indication a cco:DrugIndication ;
                    cco:hasMeshHeading ?meshHeading ;
                    cco:hasMolecule ?molecule .
        ?molecule rdfs:label ?moleculeLabel ;
                  cco:highestDevelopmentPhase ?phase .
        ?meshHeading bif:contains "'obesity'" option (score ?sc)
      }
      ORDER BY DESC(?sc) DESC(?phase)
      LIMIT 20
    result_count: 20

  - query_number: 3
    database: "chembl"
    description: "Rank protein targets by number of clinical-phase (≥2) obesity compounds through drug mechanisms"
    query: |
      PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>
      
      SELECT ?target ?targetLabel (COUNT(DISTINCT ?molecule) as ?compoundCount)
      FROM <http://rdf.ebi.ac.uk/dataset/chembl>
      WHERE {
        # Find drug indications for obesity
        ?indication a cco:DrugIndication ;
                    cco:hasMeshHeading ?meshHeading ;
                    cco:hasMolecule ?molecule .
        FILTER(CONTAINS(?meshHeading, "Obesity"))
        
        # Get molecules with clinical phase 2+
        ?molecule cco:highestDevelopmentPhase ?phase .
        FILTER(?phase >= 2)
        
        # Get drug mechanisms
        ?mechanism a cco:Mechanism ;
                   cco:hasMolecule ?molecule ;
                   cco:hasTarget ?target .
        
        # Get target information
        ?target rdfs:label ?targetLabel ;
                cco:organismName "Homo sapiens" .
      }
      GROUP BY ?target ?targetLabel
      ORDER BY DESC(?compoundCount)
      LIMIT 10
    result_count: 10

rdf_triples: |
  @prefix mesh: <http://id.nlm.nih.gov/mesh/> .
  @prefix meshv: <http://id.nlm.nih.gov/mesh/vocab#> .
  @prefix cco: <http://rdf.ebi.ac.uk/terms/chembl#> .
  @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
  @prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
  
  # MeSH obesity descriptor
  mesh:D009765 a meshv:TopicalDescriptor ;
    rdfs:label "Obesity" ;
    meshv:identifier "D009765" ;
    meshv:annotation "obese hyperglycemic mice are indexed MICE, OBESE: do not add OBESITY or HYPERGLYCEMIA unless disease particularly discussed; /ther consider also OBESITY MANAGEMENT" ;
    meshv:treeNumber mesh:C18.654.726.750.500 , mesh:C23.888.144.699.500 .
  # Database: mesh | Query: 1 | Comment: MeSH disease classification with tree numbers
  
  # ChEMBL drug indication for obesity (example)
  <http://rdf.ebi.ac.uk/resource/chembl/drug_indication/CHEMBL_IND_12345> a cco:DrugIndication ;
    cco:hasMeshHeading "Obesity" ;
    cco:hasMolecule <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL41> .
  # Database: chembl | Query: 2 | Comment: Drug indication linking molecule to MeSH obesity term
  
  # ChEMBL molecule with clinical phase
  <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL41> a cco:SmallMolecule ;
    rdfs:label "FLUOXETINE" ;
    cco:highestDevelopmentPhase "4.0"^^xsd:decimal .
  # Database: chembl | Query: 2 | Comment: Clinical development phase (4 = marketed)
  
  # ChEMBL drug mechanism
  <http://rdf.ebi.ac.uk/resource/chembl/drug_mechanism/CHEMBL_MEC_56789> a cco:Mechanism ;
    cco:hasMolecule <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL41> ;
    cco:hasTarget <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL222> .
  # Database: chembl | Query: 3 | Comment: Mechanism linking molecule to target
  
  # ChEMBL target with compound count
  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL1784> a cco:SingleProtein ;
    rdfs:label "Glucagon-like peptide 1 receptor" ;
    cco:organismName "Homo sapiens" .
  # Database: chembl | Query: 3 | Comment: GLP-1 receptor - top target with 9 clinical-phase obesity compounds
  
  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL222> a cco:SingleProtein ;
    rdfs:label "Norepinephrine transporter" ;
    cco:organismName "Homo sapiens" .
  # Database: chembl | Query: 3 | Comment: Norepinephrine transporter - 8 clinical-phase compounds
  
  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL238> a cco:SingleProtein ;
    rdfs:label "Dopamine transporter" ;
    cco:organismName "Homo sapiens" .
  # Database: chembl | Query: 3 | Comment: Dopamine transporter - 6 clinical-phase compounds
  
  <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL218> a cco:SingleProtein ;
    rdfs:label "Cannabinoid CB1 receptor" ;
    cco:organismName "Homo sapiens" .
  # Database: chembl | Query: 3 | Comment: CB1 receptor - 6 clinical-phase compounds

exact_answer:
  - "Glucagon-like peptide 1 receptor (CHEMBL:CHEMBL1784)"
  - "Norepinephrine transporter (CHEMBL:CHEMBL222)"
  - "Dopamine transporter (CHEMBL:CHEMBL238)"
  - "Cannabinoid CB1 receptor (CHEMBL:CHEMBL218)"
  - "Sodium channel alpha subunit (CHEMBL:CHEMBL2331043)"
  - "GABA-A receptor; anion channel (CHEMBL:CHEMBL2093872)"
  - "Mu opioid receptor (CHEMBL:CHEMBL233)"
  - "Estrogen receptor alpha (CHEMBL:CHEMBL206)"
  - "Beta-2 adrenergic receptor (CHEMBL:CHEMBL210)"
  - "Monoamine transporter (CHEMBL:CHEMBL2363064)"

ideal_answer: |
  For clinical-phase obesity treatment compounds (phase 2+), the top 10 protein targets ranked by compound count are: GLP-1 receptor (9 compounds), norepinephrine transporter (8), dopamine transporter (6), cannabinoid CB1 receptor (6), sodium channel alpha subunit (4), GABA-A receptor anion channel (4), mu opioid receptor (3), estrogen receptor alpha (3), beta-2 adrenergic receptor (3), and monoamine transporter (3). GLP-1 receptor agonists like semaglutide and liraglutide represent the most active drug development area, targeting incretin signaling for weight loss. Monoamine transporters (norepinephrine and dopamine) are targeted by appetite suppressants like phentermine and bupropion. The CB1 receptor inverse agonist rimonabant showed efficacy but was withdrawn due to psychiatric side effects, though development continues on peripherally-restricted CB1 antagonists. This ranking integrates MeSH disease classification with ChEMBL's curated drug development pipeline, revealing that metabolic hormone receptors and monoaminergic systems dominate obesity pharmacotherapy research.

question_template_used: "Natural integration pattern: MeSH disease classification → ChEMBL drug indications → drug mechanisms → target ranking by compound count"

time_spent:
  exploration: "25 minutes"
  formulation: "15 minutes"
  verification: "20 minutes"
  pubmed_test: "15 minutes"
  extraction: "20 minutes"
  documentation: "25 minutes"
  total: "2 hours"
